Wells Fargo & Company Caladrius Biosciences, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.41 - $0.74 $14 - $25	35 Added 9.43%	406 $0
Q1 2022 May 16, 2022	BUY	$0.63 - $1.03 $0 - $1	1 Added 0.27%	371 $0
Q4 2021 Feb 14, 2022	BUY	$0.83 - $1.22 $1 - $2	2 Added 0.54%	370 $0
Q3 2021 Nov 15, 2021	BUY	$1.15 - $1.57 $64 - $87	56 Added 17.95%	368 $0
Q2 2021 Aug 16, 2021	SELL	$1.4 - $1.9 $19 - $26	-14 Reduced 4.29%	312 $0

Q1 2021 May 13, 2021	BUY	$1.44 - $2.89 $315 - $632	219 Added 204.67%	326 $1,000
Q4 2020 Feb 09, 2021	BUY	$1.39 - $1.87 $8 - $11	6 Added 5.94%	107 $0
Q3 2020 Nov 05, 2020	BUY	$1.6 - $3.0 $75 - $141	47 Added 87.04%	101 $0
Q1 2020 May 14, 2020	BUY	$1.21 - $3.47 $65 - $187	54 New	54 $0

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.